---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-22-000047"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:57:16.260732+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss

## Summary
- Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.
- Operating loss $63.1M (vs $10.3M); net loss $64.5M (vs $11.1M); stock-based comp $36.3M.
- FY2022 revenue guidance cut to $500-520M (2-6% growth) from prior expectations.
- Headwinds: China lockdowns, European cold-chain logistics delays, execution issues, unfavorable FX.
- Launched Fixed RNA Profiling Kit for FFPE; shipped Visium CytAssist; hired Jim Wilbur as CCO.

## SEC filing metadata
- accession: 0001770787-22-000047
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/0001770787-22-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/txg-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-22-000047
- JSON: https://secwatch.observer/filing/0001770787-22-000047.json
- Plain text: https://secwatch.observer/filing/0001770787-22-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.